Saroglitazar: A New Drug to Treat Diabetic Hypertriglyceridemia
DOI:
https://doi.org/10.17140/HROJ-4-135Abstract
Dyslipidemia alone has been considered as one of the major modifiable risk factor for cardiovascular
diseases (CVD) accounting for 50% of the 1st myocardial infarction (MI) cases
worldwide.1 A recent epidemiological survey on prevalence of lipid abnormalities of the Indian
population by Indian Council of Medical Research-India Diabetes Study (ICMR-INDIAB), has
shown that 79% of Indian subjects above 20 years of age have abnormalities in at least one of
the lipid parameters.2 In this survey, the most commonly found lipid abnormality was low-high
density lipoprotein cholesterol (low HDL-C) in 72% subjects followed by high triglycerides
(TG) in 29.5% subjects and then high low-density lipoprotein cholesterol (LDL-C) in 11.8%
subjects.3 Prevalence of dyslipidemia is high in India, which calls for urgent lifestyle and pharmacological
intervention strategies to prevent and manage this important cardiovascular risk
factor.
References
Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). Lancet. 2004; 364: 937-952. doi: 10.1016/S0140-6736(04)17018-9
La Rosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled tri-als. JAMA. 1999; 282: 2340-2346. Web site. http://citeseerx.ist. psu.edu/viewdoc/download?doi=10.1.1.596.2772&rep=rep1&t ype=pdf. Accessed October 4, 2016.
Joshi SR, Anjana RM, Deepa M, et al. Prevalence of dyslipid-emia in urban and rural India: The ICMR–INDIAB Study. PLOS ONE. 2014; 9(5): e96808. doi: 10.1371/journal.pone.0096808
Baigent C, Keech A, Kearney PM, et al. Cholesterol treat-ment trialists (CTT) collaborators. Efficacy and safety of choles-terol lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005; 366: 1267-1278. doi: 10.1016/S0140-6736(05)67394-1
Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Journal of the Ameri-can College of Cardiology. 2006; 483: 438-445.
Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syn-dromes. N Engl J Med. 2004; 350: 1495-1504. doi: 10.1056/ NEJMoa040583
Adapted from HPS Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: A randomized placebo-controlled tri-al. Lancet. 2002; 360: 7-22.
Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors, the prospective pravastatin pooling project. Circu-lation. 2000; 102: 1893-900. doi: 10.1161/01.CIR.102.16.1893
Miller M. Current perspectives on the management of hyper-triglyceridemia. Am Heart J. 2000; 140: 232-240. doi: 10.1067/ mhj.2000.108001
Austin MA, Hokanson JE, Edwards KL. Hypertriglyceride-mia as a cardiovascular risk factor. Am J Cardiol. 1998; 81: 7B-12B. doi: 10.1016/S0002-9149(98)00031-9
Miller M. Is hypertriglyceridaemia an independent risk fac-tor for coronary heart disease? The epidemiological evidence. Eur Heart J. 1998; 19 (Suppl H): H18-H22. Web site. http://eu-ropepmc.org/abstract/med/9717060. Accessed October 4, 2016.
Jørgensen A, Frikke-Schmidt R, Nordestgaard B. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014; 371: 32-41. doi: 10.1056/NEJ Moa1308027
Miller M, Cannon CP, Murphy SA, et al. Impact of triglycer-ide levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008; 724-730. doi: 10.1016/j.jacc.2007.10.038
Schwartz G, Abt M, Bao W, et al. Fasting triglycerides pre-dict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015; 65(21): 2267-2275. doi: 10.1016/j.jacc.2015.03.544
Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010; 363(7): 692-694. doi: 10.1056/NEJMc1006407
Garber A, Abrahamson M, Barzilay J, et al. Consensus State-ment by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehen-sive Type 2 Diabetes Management Algorithm–2016 Execu-tive Summary. Endocr Pract. 2016; 22: 84-113. doi: 10.4158 /EP151126.CS
Iyengar S, Puri R, Narasingan SN. Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2016, Part 1. J Assoc Physicians India. 2016; 7-52.
Reiner Ž, Catapano AL, de Backer G, et al. ESC/EAS Guide-lines for the management of dyslipidaemias. European Heart Journal. doi: 10.1093/eurheartj/ehr158
Fredenrich A, Grimaldi PA. PPAR delta. An uncompletely known nuclear receptor. Diabetes Metab. 2005; 31: 23-27. doi: 10.1016/S1262-3636(07)70162-3
Munigoti SP, Harinarayan CV. Role of glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone. Indian J Endocrinol Metab. 2014; 18(3): 283-287. doi: 10.4103/2230- 8210.131134
Jani H, Kansagra K, Jain MR, Patel H. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects. Clin Drug Investig. 2013; 33(11): 809-816. doi: 10.1007/s40261-013-0128-3
Jain M, Giri S, Trivedi C, et al. Saroglitazar, a novel PPAR α/γ agonist with predominant PPAR α activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect. 2015; 3(3): e00136. doi: 10.1002/prp2.136
Jani RH, Kansagra K, Jain MR, Patel H. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects. Clin Drug Investig. 2013; 33(11): 809-816. doi: 10.1007/s40261-013-0128-3
Pai V, PaneerselvamA, Mukhopadhyay S, et al.AMulticenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). J Diabetes Sci Technol. 2014; 8(1):132-141. doi: 10.1177/ 1932296813518680
Jani R, Pai V, Jha P, et al. A multicenter, prospective, random-ized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared with placebo in type 2 diabe-tes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technology & Therapeutics. 2014; 16(2): 63-71. doi: 10.1089/dia.2013.0253
Shetty S, Kumar S, Mathur R, Sharma K, Jaiswal A. Obser-vational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients. Indian Heart Journal. 2015; 67(1): 23-26. doi: 10.1016/j.ihj.2015.02.007
Joshi S, Sound R, Saboo B. Efficacy and Safety of Saroglita-zar in Indian Diabetics-two year data. Adapted from ADA 2016; Poster no: 40-LB: http://www.prnewswire.com/news-releases/ new-scientific-data-of-investigational-lipaglyntm-saroglitazar-and-real-world-data-in-patients-will-be-featured-at-american-diabetes-association-ada-76th-scientific-sessions-582573961. html. Accessed October 4, 2016.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.